Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patients report for 2015 and annual treatment report for 2010

Abstract

Aim: To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2015 and the Annual Treatment Report for 2010 on the outcomes of patients who started treatment in 2010. Methods: The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment was initiated in 2015 were analyzed retrospectively. Survival of the patients who started treatment in 2010 was analyzed by using the Kaplan-Meier, log-rank and Wilcoxson tests. Results: Treatment was initiated in 2015 for 7527 patients with cervical cancer, 10 119 with endometrial cancer, 6424 with ovarian cancer and 2181 with ovarian borderline tumors. This clinicopathological information was summarized as the Patient Annual Report. Prognoses were analyzed across 4309 patients with cervical cancer, 5054 with endometrial cancer and 3423 with ovarian cancer, whose treatment was initiated in 2010. The 5-year survival rates of the patients with cervical cancer were 92.1%, 74.2%, 52.0%, and 29.8% for stages I, II, III, and IV, respectively. The 5-year survival rates for the patients with endometrial cancer were 94.3%, 88.8%, 74.0% and 26.6% for stages I, II, III and IV, respectively. The 5-year survival rates for the patients with ovarian cancer (surface epithelial-stromal tumors) were 88.5%, 80.1%, 46.3% and 36.2% for stages I, II, III and IV, respectively. Conclusion: The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.

Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy

“…Small cell carcinoma is a fast-growing tumor with neuroendocrine differentiation that usually occurs in the lungs. In Japan, small cell carcinoma of the uterine cervix is very rare, accounting for only 1.3% of uterine cervical carcinomas [1]; therefore, it is difficult to conduct a prospective study. The poor prognosis is because of early lymph node development, distant organ metastases, and vascular invasion, which are risk factors for recurrence [2,3].…”

“…Small cell carcinoma of the uterine cervix is a very aggressive neuroendocrine tumor that accounts for only 1.3% of cervical cancers [1]. Lymph node metastasis and distant metastasis can occur at an early stage with poor outcomes [2,3].…”

A retrospective study for investigating the relationship between old and new staging systems with prognosis in ovarian cancer using gynecologic cancer registry of Japan Society of Obstetrics and Gynecology (JSOG): disparity between serous carcinoma and clear cell carcinoma

“…The main treatments for ovarian cancer are surgery and chemotherapy, and the effect of treatment affects the prognosis. In Japan, the incidence of ovarian clear cell carcinoma, which is resistant to chemotherapy, is higher than that in the West [2][3][4]. This raises the question of whether FIGO staging created mainly in Western countries with a large number of patients with chemosensitive serous carcinoma is useful in Japan, in which there is a large number of patients with chemoresistant clear cell carcinoma.…”

“…In Japan, the Japan Society of Obstetrics and Gynecology (JSOG) maintains a gynecological cancer registry (GCR) to collect information on clinicopathological factors and prognosis of patients with ovarian cancer and ovarian borderline malignant tumor [2,3]. Based on the registered patients in the GCR, the JSOG member facilities have extensive therapeutic experience in gynecological cancer treatment.…”

Survey of the desire to have children and engage in sexual activity after trachelectomy among young Japanese women with early‐stage cervical cancer

“…The incidence of cervical cancer has been increasing in Japan in recent years, particularly in young women . Accordingly, the number of cervical cancer patients who require fertility preservation has also increased.…”